Drug Trial Radar · NCT06185764
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Actual
Start
Feb 20, 2024
Primary completion
Feb 2, 2027
Study completion Feb 2, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Dec 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VX-670 at different single and multiple doses in participants with DM1.
Conditions
- Myotonic Dystrophy Type 1 (DM1)
Interventions
VX-670Drug
Solution for intravenous administration.
PlaceboDrug
Solution for intravenous administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)Time frame: Part A: From Baseline up to Day 42; Part B: From Baseline and up to Day 168
Locations
26 sites in 10 countries. Site status is shown where the registry gives one.
Stanford Neuromuscular Research
San Carlos, California
University of Florida Clinical Research Center
Gainesville, Florida
University of Kansas Medical Center
Fairway, Kansas
Boston Children's Hospital
Boston, Massachusetts
Washington University School of Medicine / St. Louis Children's Hospital
St Louis, Missouri
Wake Forest Baptist Health
Winston-Salem, North Carolina
University of Pennsylvania
Philadelphia, Pennsylvania
Virginia Commonwealth University (Sanger Hall)
Richmond, Virginia
Wesley Research Institute
Auchenflower, Australia
Neuroscience Clinical Trials Unit, Alfred Brain
Melbourne, Australia
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Hopital de Chicoutimi
Chicoutimi, Canada
Altasciences Montreal
Montreal, Canada
McGIll University
Montreal, Canada
University of Ottawa
Ottawa, Canada
CHU Research Centre of Quebec
Québec, Canada
Neuromuscular Reference Center Institute of Myology
Paris, France
Ludwig Maximilians Universitaet Muenchen
München, Germany
Centro Clinico NeMO
Milan, Italy
Maastricht University Medical Center
Maastricht, Netherlands
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Clinical Research Facility, Queen Elizabeth University Hospital
Glasgow, United Kingdom
Leonard Wolfson Experimental Neurology Centre CRF
London, United Kingdom
St. George's University Hospital
London, United Kingdom
Salford Royal Hospital
Salford, United Kingdom
Royal Hallamshire Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.